Tumor profiling tests may also offer immunohistochemistry (IHC) testing to characterize expression of biomarkers such as HER2, PD-L1 and mismatch repair (MMR) proteins, which can identify patients who may benefit from anti-HER2 and immune-based therapies. Here, ERBB2 is linked to neoplasm.